There is limited data to suggest that myeloneuropathies exist within the spectrum of classical paraneoplastic syndromes.

Among thirty-two patients with paraneoplastic myeloneuropathy, twenty-six had detectable onconeural antibodies (Amphiphysin, 8; ANNA-1/anti-Hu, 6; CRMP-5, 5; PCA-1/anti-Yo, 2; PCA-2, 1; Kelch-like-Protein-11, 1; combinations thereof: ANNA-1 and CRMP-5, 1; ANNA-1 and Amphiphysin, 1; ANNA-3 and CRMP-5,1). Among these, twenty-two had underlying malignancy (small-cell lung cancer, 10), and four had lung nodules/masses (not evaluated further). Six patients had malignancies without classified onconeural antibodies (unclassified neural-autoantibodies, 3). Weight loss (>10 lbs, 63%), bowel/bladder dysfunction (69%) and gastrointestinal dysmotility (46%) were common presenting symptoms. The majority of neuropathies were non-length dependent (88%), asymmetric (69%), and presented with dysesthesia at onset (63%). A considerable proportion had polyradicular localization (56%). Co-existing upper and lower motor neuron involvement was documented on initial examination in 81%. However, 56% initially received an alternative diagnosis. Inflammatory CSF was noted in 82% (median nucleated-cell count, 13 cell/mm³ [range 0-74]). Tract-specific changes on cervical/thoracic MRI were seen in 9/29(31%) patients.  In comparison to copper-deficiency myeloneuropathy (n=11), asymmetric sensory presentations, subacute progression, anorexia/weight loss, dysautonomia, taste/smell alterations, inflammatory CSF and gadolinium enhancement of spinal cord or lumbosacral roots were significantly more frequent in paraneoplastic myeloneuropathies (p<0.05). Ten of thirty-one (32%) paraneoplastic patients with long-term follow-up data were wheelchair bound at last follow-up. Median modified-Rankin-Score at last follow-up was 3 (range 1-6).